We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

Back to rankings

46 hedge funds and large institutions have $45.4M invested in Osiris Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

53% more capital invested

Capital invested by funds: $29.6M → $45.4M (+$15.8M)

44% more funds holding

Funds holding: 32 → 46 (+14)

Holders
46
Holders Change
+14
Holders Change %
+43.75%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
12
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Cloverdale Capital Management
Texas
+$6.68M
2
GF
Gabelli Funds
New York
+$1.49M
3
EGI
EAM Global Investors
California
+$988K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$983K
5
EI
EAM Investors
California
+$767K

Top Sellers

Rank Fund Capital Flow
1
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$5.71M
2
BRF
B. Riley Financial
California
-$303K
3
Deutsche Bank
Deutsche Bank
Germany
-$275K
4
WSTAM
Wilbanks Smith & Thomas Asset Management
Virginia
-$61K
5
Bank of America
Bank of America
North Carolina
-$22.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
26
Centiva Capital
New York
$191K +$158K +14,127 New
OAM
27
Oxford Asset Management
United Kingdom
$178K +$147K +13,179 New
SG Americas Securities
28
SG Americas Securities
New York
$168K -$2.95K -264 -2%
Goldman Sachs
29
Goldman Sachs
New York
$162K +$134K +11,981 New
State Street
30
State Street
Massachusetts
$157K +$130K +11,600 New
VF
31
Virtu Financial
New York
$147K +$122K +10,895 New
TI
32
Trexquant Investment
Connecticut
$145K +$120K +10,732 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$138K – – –
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$110K +$90.5K +8,100 New
UBS Group
35
UBS Group
Switzerland
$84K – – –
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$41K – – –
Bank of America
37
Bank of America
North Carolina
$39K -$22.5K -2,014 -41%
Deutsche Bank
38
Deutsche Bank
Germany
$20K -$275K -24,640 -94%
DWA
39
Dorsey Wright & Associates
California
$16K +$13.3K +1,194 New
Morgan Stanley
40
Morgan Stanley
New York
$8K +$4.19K +375 +150%
VFA
41
Valeo Financial Advisors
Indiana
$3K – – –
AG
42
Advisor Group
Arizona
$1K – – –
NCM
43
Next Capital Management
New York
$1K +$447 +40 New
OSAM
44
O'Shaughnessy Asset Management
Connecticut
$1K +$548 +49 New
FGC
45
Financial Gravity Companies
Texas
$1K +$760 +68 New
QT
46
Quantamental Technologies
New York
$1K +$1.12K +100 New
WSTAM
47
Wilbanks Smith & Thomas Asset Management
Virginia
– -$61K -5,500 Closed
LTFS
48
Ladenburg Thalmann Financial Services
Florida
– -$6K -500 Closed
Group One Trading
49
Group One Trading
Illinois
– -$1K -66 Closed
1
2

OSIR Hedge Fund Activity: Q4 2018 in Review

46 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2018, worth a combined $45.4M — up 53% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OSIR positions and 3 closed out — a net gain of 15 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Cloverdale Capital Management, opening a new position worth an estimated $6.68M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $5.71M.

  • 46 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2018, up from 32 in Q3 2018.
  • Funds reported $45.4M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2018, up 53% quarter-over-quarter.
  • 18 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +15 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2018 was Cloverdale Capital Management, an estimated $6.68M added.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2018 was Manulife (Manufacturers Life Insurance), an estimated $5.71M sold.

Based on aggregated 13F filings for Q4 2018.